Welcome to our dedicated page for NewcelX news (Ticker: NCEL), a resource for investors and traders seeking the latest updates and insights on NewcelX stock.
NewcelX Ltd. (Nasdaq: NCEL) is a Zurich-based clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The NewcelX news feed on Stock Titan highlights company announcements that shed light on its ALS, Type 1 Diabetes, and CNS-focused programs, as well as its broader strategy in regenerative medicine and neuroscience.
Investors and observers can follow updates on AstroRx®, NewcelX’s cell-therapy program for ALS, and IsletRx, its stem-cell–derived islet therapy for insulin-dependent Type 1 Diabetes. News items include results from international collaborative studies on biomaterial approaches for stem-cell–derived islet delivery, which explore engineered scaffolds and extracellular matrix integration to support islet function and potentially reduce the need for chronic immunosuppression.
The news stream also covers developments in the DOXA small-molecule platform, such as publication of patent applications in key markets like China for quinazoline, benzothiazine, and benzoxazine derivatives targeting neurological diseases. These updates provide insight into how NewcelX is expanding its intellectual property footprint and advancing CNS drug discovery linked to sleep-wake regulation, orexin signaling, and metabolic control.
Additional coverage features scientific and strategic appointments to the company’s Scientific Advisory Board, reflecting expertise in diabetes innovation, ALS, neuroimmunology, and stem-cell-based regenerative medicine. Corporate communications, including shareholder letters and roadmap updates following the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., offer context on NewcelX’s integrated platform, clinical plans, and financial positioning. For readers tracking NCEL, this news page brings together scientific, clinical, intellectual property, and governance milestones in one place.
NewcelX (Nasdaq: NCEL) announced that the Brazilian Patent and Trademark Office has granted Patent BR 112018010946-0, covering its cell selection and enrichment manufacturing process for lead candidate NCEL-101 for type 1 diabetes. The patent runs until November 2036 and complements the existing U.S. portfolio.
According to NewcelX, Brazil has about 500,000 people with type 1 diabetes, with prevalence growing 4.4% annually. NCEL-101 has shown favorable preclinical data, including ~60% beta cells co-expressing insulin and NKX6.1/MAFA, 99.98% endocrine lineage, and over 96% non-proliferative cells. The company recently completed a Type B Pre-IND meeting with the FDA for NCEL-101 in combination with Eledon's tegoprubart, supporting plans to initiate clinical activities.
NewcelX (Nasdaq: NCEL) appointed diabetes research pioneer Dr. Camillo Ricordi to its Scientific Advisory Board following a successful FDA Type B Pre-IND meeting for NCEL-101, which, according to NewcelX, provided a clear regulatory pathway toward clinical trials in type 1 diabetes.
Dr. Ricordi will advise NewcelX’s regenerative medicine and beta-cell replacement strategy, supporting its type 1 diabetes program and strategic collaboration with Eledon Pharmaceuticals aimed at stem cell-derived islet replacement combined with targeted immune modulation.
NewcelX (Nasdaq: NCEL) reported a successful FDA Type B Pre-IND meeting for NCEL-101 in combination with tegoprubart for type 1 diabetes.
The FDA aligned with the proposed development strategy and gave favorable CMC and preclinical feedback, allowing progression toward IND-enabling activities and planned clinical trials.
According to NewcelX, NCEL-101 showed ~60% beta cells co-expressing insulin and NKX6.1, 99.98% endocrine lineage, and over 96% non-proliferative cells in preclinical studies. Tegoprubart has been used as an investigational immunosuppressive in more than 100 transplant recipients and in a 12-patient type 1 diabetes study.
NewcelX (Nasdaq: NCEL) submitted a Pre-IND briefing package to the FDA for NCEL-101, a stem cell-derived islet therapy for type 1 diabetes, in combination with Eledon’s tegoprubart.
A Type B pre-IND meeting is scheduled for late June to review manufacturing, preclinical plans and First-In-Human trial design.
NewcelX (Nasdaq: NCEL) reported 2025 results and outlined plans to accelerate development of its flagship Type 1 Diabetes program, NCEL-101, in collaboration with Eledon Pharmaceuticals for 2026. Key facts: completed a merger, secured financing of up to approximately $3.4M (including $1.35M cash), maintains access to a $25M equity line, and held $2.2M cash at year-end. 2025 net loss was $8.3M (including $5.7M non-cash finance expenses); net cash used in operations was $2.8M. Company added Julien Boisdron, MD to its scientific advisory board and noted manufacturing preparations with CDMO Pluri Inc.
NewcelX (Nasdaq: NCEL) updated its corporate presentation to spotlight its flagship Type 1 Diabetes program NCEL-101 and a strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN). The presentation describes integrating NewcelX’s stem-cell-derived islet replacement platform with Eledon’s anti-CD40L antibody tegoprubart to address immune-mediated transplant rejection.
Management will present the updated materials at the upcoming Swiss Biotech Conference to outline the combined development strategy and potential for durable graft survival toward a functional cure for Type 1 Diabetes.
NewcelX (Nasdaq: NCEL) announced a private placement priced at $2.75 per share, a 30% premium to the March 31, 2026 close, selling 490,907 common shares and warrants to purchase 687,270 shares at a $3.025 exercise price.
Proceeds, together with a previously announced $25 million equity line, are intended to advance NCEL-101 for Type 1 Diabetes, other pipeline programs, working capital and general corporate purposes; closing is expected on or about April 15, 2026 subject to customary conditions.
NewcelX (Nasdaq: NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (Nasdaq: ELDN) to evaluate combination strategies pairing NewcelX's lead stem-cell-derived islet program, NCEL-101, with Eledon's anti-CD40L antibody tegoprubart (AT-1501).
The collaboration leverages clinical experience from >100 transplant patients treated with tegoprubart and aims to support durable, immune-protected islet replacement, potentially clarifying regulatory pathways and accelerating NCEL-101 development toward pivotal milestones.
NewcelX (Nasdaq: NCEL) announced a peer-reviewed publication on Mazindol IR/SR in Clinical Drug Investigation, strengthening the scientific case for Mazindol ER under its CVR framework. The paper is cited via DOI and is said to bolster licensing and acquisition negotiations to maximize CVR value realization.
Management reports advanced, structured discussions with multiple counterparties and highlights IP dating to 2006 and over 20 years of research supporting CNS indications including narcolepsy, ADHD, and substance use disorders.
NewcelX (NASDAQ: NCEL) released an updated corporate presentation on Jan 29, 2026, ahead of spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon. The deck emphasizes a sharpened strategic focus on Type 1 Diabetes cell therapy, recent scientific progress, clinical priorities, and new Scientific Advisory Board and leadership appointments to support near- and mid-term value-creation milestones.
Management will be available for one-on-one meetings at upcoming conferences and the presentation is available on the company website.